Plain-English translation of NCT06324357 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to see if it can help shrink tumors in people with advanced HER2-positive cancers (breast, stomach, or colorectal cancer that has spread). The study will also test whether works better when combined with other cancer drugs already used to treat these conditions. Researchers will carefully monitor participants to find the best dose and combination that patients can tolerate safely.
HER2 is a protein that causes cancer cells to grow, and many advanced cancers have too much of it. This medication is designed to block HER2, but doctors need to find the best doses and combinations with other treatments to help patients while minimizing side effects.
You likely qualify if…
You likely don't qualify if…
Participants will take as a tablet by mouth, either alone or combined with other cancer medications, in treatment cycles. You will visit the study site regularly for blood tests, heart monitoring, and imaging scans (CT or MRI) to check if your tumor is shrinking. The study has two phases: first, doctors will test increasing doses to find what patients can tolerate, and then they will enroll more patients on the best doses to confirm how well the treatment works.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States